Identification of patients on chronic prescription opioids at risk for opioid use disorder using pharmacy claims data

Q3 Medicine
Aleesha Jantzen Pharm.D., Scott Thomas Hall Pharm.D., Benjamin Lai MB BCh BAO, Julie L. Cunningham Pharm.D., Laura Odell Pharm.D., MPH
{"title":"Identification of patients on chronic prescription opioids at risk for opioid use disorder using pharmacy claims data","authors":"Aleesha Jantzen Pharm.D.,&nbsp;Scott Thomas Hall Pharm.D.,&nbsp;Benjamin Lai MB BCh BAO,&nbsp;Julie L. Cunningham Pharm.D.,&nbsp;Laura Odell Pharm.D., MPH","doi":"10.1002/jhrm.21585","DOIUrl":null,"url":null,"abstract":"<p>Using pharmacy claims data from a single commercial health plan to identify opportunities for opioid use disorder (OUD) focused screening and interventions communicated via targeted prescriber messaging. Participants included members ≥18 years using more than 90 morphine milligram equivalents (MMED) daily based on all opioid claims, had &gt;1 paid claim for an opioid product, and had ≥90 days of total opioid therapy. Members were excluded with ≥1 claims for an oral chemotherapy agent (except methotrexate). Intervention was completed with a secure communication to the primary outpatient opioid prescriber that included resources for diagnosis, treatment, and best practices for opioid prescribing. The main outcome measure was any documented change to opioid use following the intervention. Seven hundred forty-five members were identified; a subset (<i>n</i> = 20) was further assessed, and all had identified OUD risk factors; providers were subsequently sent a communication. Sixteen providers acknowledged receipt and 11 patients (55%) had at least one documented intervention following communication receipt. Provision of targeted, evidence-based recommendations to providers for patients identified to be at risk of OUD from pharmacy claims data can result in increased recognition and intervention. Future efforts to explore feasibility of provider education detailing efforts and continued evaluation of efficacy are needed.</p>","PeriodicalId":39819,"journal":{"name":"Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management","volume":"44 2","pages":"14-19"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhrm.21585","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Using pharmacy claims data from a single commercial health plan to identify opportunities for opioid use disorder (OUD) focused screening and interventions communicated via targeted prescriber messaging. Participants included members ≥18 years using more than 90 morphine milligram equivalents (MMED) daily based on all opioid claims, had >1 paid claim for an opioid product, and had ≥90 days of total opioid therapy. Members were excluded with ≥1 claims for an oral chemotherapy agent (except methotrexate). Intervention was completed with a secure communication to the primary outpatient opioid prescriber that included resources for diagnosis, treatment, and best practices for opioid prescribing. The main outcome measure was any documented change to opioid use following the intervention. Seven hundred forty-five members were identified; a subset (n = 20) was further assessed, and all had identified OUD risk factors; providers were subsequently sent a communication. Sixteen providers acknowledged receipt and 11 patients (55%) had at least one documented intervention following communication receipt. Provision of targeted, evidence-based recommendations to providers for patients identified to be at risk of OUD from pharmacy claims data can result in increased recognition and intervention. Future efforts to explore feasibility of provider education detailing efforts and continued evaluation of efficacy are needed.

利用药房报销数据识别有阿片类药物使用障碍风险的长期处方阿片类药物患者。
利用来自单一商业健康计划的药房理赔数据,确定通过有针对性的处方信息进行阿片类药物使用障碍(OUD)重点筛查和干预的机会。参与者包括根据所有阿片类药物报销单每天使用超过 90 吗啡毫克当量 (MMED) 的≥18 岁的会员,有 >1 次阿片类药物产品的付费报销单,且阿片类药物治疗总天数≥90 天。口服化疗药物(甲氨蝶呤除外)报销次数≥1 次的成员不包括在内。通过与阿片类药物主要门诊处方者的安全通信完成干预,其中包括诊断、治疗和阿片类药物处方最佳实践的资源。主要结果指标是干预后阿片类药物使用的任何有记录的变化。共确定了 745 名成员;进一步评估了一个子集(n = 20),所有成员都有已确定的 OUD 风险因素;随后向医疗服务提供者发送了沟通信息。16 名医疗服务提供者确认收到了信息,11 名患者(55%)在收到信息后进行了至少一次记录在案的干预。向医疗服务提供者提供有针对性的循证建议,帮助他们从药房报销数据中识别出有 OUD 风险的患者,可以提高识别率和干预率。今后需要努力探索医疗服务提供者详细教育工作的可行性,并继续对其效果进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
44
期刊介绍: The Journal of Healthcare Risk Management is published quarterly by the American Society for Healthcare Risk Management (ASHRM). The purpose of the journal is to publish research, trends, and new developments in the field of healthcare risk management with the ultimate goal of advancing safe and trusted patient-centered healthcare delivery and promoting proactive and innovative management of organization-wide risk. The journal focuses on insightful, peer-reviewed content that relates to patient safety, emergency preparedness, insurance, legal, leadership, and other timely healthcare risk management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信